Juno Therapeutics announced last week that it was placing a voluntary hold on its clinical trial of JCAR015 — an experimental but promising immunotherapy treatment for patients with advanced leukemia — after two patients in the trial died of cerebral edema, or brain swelling.

JCAR015 is Juno’s flagship product, and the most advanced clinical trial the company is currently pursuing.

The recent deaths throw the future of the therapy into doubt and highlight the uncertainty surrounding immunotherapy treatments.

Read the full article on GeekWire